Literature DB >> 19327876

Development of hypertriglyceridemia in patients with enterocutaneous fistulas.

Ruben G J Visschers1, Steven W M Olde Damink, Malou Schreurs, Bjorn Winkens, Peter B Soeters, Wim G van Gemert.   

Abstract

BACKGROUND & AIMS: Hypertriglyceridemia is commonly observed in patients with enterocutaneous fistulas, compromising their health status. In this study potential causes for hypertriglyceridemia in patients with an enterocutaneous fistula are explored and treatment options discussed accordingly.
METHODS: A database was created consisting of all consecutively treated patients with an enterocutaneous fistula from 1991 until 2007. Two successive measures of serum triglyceride concentrations of more than 3.0 mmol/L (266 mg/dL) were regarded as hypertriglyceridemia. The relation between fistula specific characteristics and hypertriglyceridemia was analyzed using a multivariable Cox proportional hazard model with time-dependent covariates.
RESULTS: A total 102 patients were eligible for this study of whom 25 had hypertriglyceridemia. Multivariable analysis showed that sepsis (HR 4.503, CI 1.778-11.401, P=0.002), high output small bowel fistula (HR 3.534, CI 1.260-9.916, P=0.016), parenteral nutrition (HR 5.689, CI 1.234-26.216, P=0.026) and inflammatory diseases (inflammatory bowel disease vs. malignancy HR 6.211, CI 1.081-35.696, P=0.041) were independent predictors of hypertriglyceridemia.
CONCLUSIONS: High triglyceride concentrations in patients with an enterocutaneous fistula were mainly associated with sepsis, a high output small bowel fistula, nutrition by the parenteral route and primary diseases with inflammatory aetiology. This should direct a treatment strategy that focuses on these aspects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19327876     DOI: 10.1016/j.clnu.2009.03.001

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  6 in total

1.  Genetic association of apolipoprotein E polymorphisms with inflammatory bowel disease.

Authors:  Ebtissam Saleh Al-Meghaiseeb; Mulfi Mubarak Al-Otaibi; Abdulrahman Al-Robayan; Reem Al-Amro; Ahmd Saad Al-Malki; Misbahul Arfin; Abdulrahman K Al-Asmari
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 2.  A serendipitous voyage in the field of nutrition and metabolism in health and disease: a translational adventure.

Authors:  Peter B Soeters
Journal:  Eur J Clin Nutr       Date:  2020-02-14       Impact factor: 4.016

3.  Lipopolysaccharide binding protein, obesity status and incidence of metabolic syndrome: a prospective study among middle-aged and older Chinese.

Authors:  Xin Liu; Ling Lu; Pang Yao; Yiwei Ma; Feijie Wang; Qianlu Jin; Xingwang Ye; Huaixing Li; Frank B Hu; Liang Sun; Xu Lin
Journal:  Diabetologia       Date:  2014-06-08       Impact factor: 10.122

4.  A Novel Approach to Major Surgery: Tracking Its Pathophysiologic Footprints.

Authors:  Styliani Mantziari; Martin Hübner; Pauline Coti-Bertrand; François Pralong; Nicolas Demartines; Markus Schäfer
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

Review 5.  An overview of lipid abnormalities in patients with inflammatory bowel disease.

Authors:  Aris P Agouridis; Moses Elisaf; Haralampos J Milionis
Journal:  Ann Gastroenterol       Date:  2011

6.  FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease.

Authors:  Kiran V K Koelfat; Ruben G J Visschers; Caroline M J M Hodin; D Rudi de Waart; Wim G van Gemert; Jack P M Cleutjens; Marion J Gijbels; Ronit Shiri-Sverdlov; Rajeshwar P Mookerjee; Kaatje Lenaerts; Frank G Schaap; Olde Damink Steven W M
Journal:  J Clin Transl Res       Date:  2017-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.